How much revenue does Avivagen make?

Avivagen reported 939,173 CAD in revenue for fiscal year 2022, down 27.5% from 1.30 million CAD in fiscal year 2021. In Q3 2023 revenue was 40,525 CAD.

What companies are similar to Avivagen?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Abattis Bioceuticals Corp. (ATTBF), Golden Developing Solutions, Inc. (DVLP), Eden Empire Inc. (EDNEF), TransCanna Holdings Inc. (TCNAF).

Avivagen Inc. (VIVXF) Stock

About Avivagen Inc.

Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in the United States, Mexi...

At a glance

Avivagen reported revenue of 939,173 CAD for fiscal year 2022, down 27.5% from fiscal year 2021, and net income of -6.07 million CAD. In Q3 2023 (the quarter ended July 31, 2023) revenue was 40,525 CAD, down 16.6% from a year before.

Figures from company filings; latest fiscal year ended October 31, 2022.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.